Synovial fluid markers of osteoarthritis in dogs.
Although none of these markers currently have any clinical applications, researchers have made strong advances in understanding molecular markers of OA and remain optimistic that the goal of identifying clinically useful markers of OA is attainable.(3-6,8,9) Much of this positive sentiment arises from the large array of molecules that have been identified.(8) Molecular markers of the greatest potential clinical use will be those that allow early detection of OA, permit disease progression to be monitored, or allow efficacy of various treatment regimens to be assessed. Earlier and more sensitive detection of OA changes may increase effective opportunities for treatment intervention during reversible phases of the OA disease process and allow more objective assessment of treatment efficacy and prognosis.(6)
Fox
D B
DB
Comparative Orthopaedic Laboratory, Veterinary Medical Teaching Hospital, University of Missouri, Columbia 65211, USA.
Cook
J L
JL
D000818:Animals; D015415:Biomarkers / Q000032:analysis*; D002358:Cartilage, Articular / Q000378:metabolism; D002809:Chondroitin Sulfates / Q000032:analysis; D004195:Disease Models, Animal; D004283:Dog Diseases / Q000175:diagnosis* / Q000378:metabolism / Q000473:pathology; D004285:Dogs; D005269:Femur / Q000473:pathology; D007632:Keratan Sulfate / Q000032:analysis; D019278:Matrix Metalloproteinase 3 / Q000032:analysis; D010003:Osteoarthritis / Q000175:diagnosis / Q000378:metabolism / Q000473:pathology / Q000662:veterinary*; D013582:Synovial Fluid / Q000737:chemistry* / Q000378:metabolism
D015415:Biomarkers; D002809:Chondroitin Sulfates; D007632:Keratan Sulfate; D019278:Matrix Metalloproteinase 3